During its full-year results presentation, CDMO and API supplier EuroAPI announced the launch of Focus-2027, a comprehensive project that will seek to unlock profitable growth and increase returns. Key means of achieving include:

* Streamlining the value-added API portfolio by discontinuing 13 with low or negative margins and focusing on highly differentiated, profitable products, such as vitamin B12, prostaglandins, peptides and oligonucleotides

* Having a focused CDMO offer “leveraging our recognised capabilities and technology platforms” *

CDMO EuroAPI has been listed on the Euronext Paris market as of 5 May. CEO Karl Rotthier said that the listing “marks an exciting milestone for the development of our company as it will enable us to consolidate our leadership in the dynamic API market”.

Sanofi has announced that newly established API manufacturer EuroAPI will begin trading on the Euronext Paris on 6 May, subject to shareholder approval at a meeting three days before. Following this, EuroAPI will operate independently.

“This important step towards our listing is a key milestone for EuroAPI and is part of the deployment of our strategy and our independence from Sanofi,” said CEO Karl Rotthier.

Big Pharma giant Sanofi has revealed that the name of its new subsidiary in third party API manufacture, as originally announced in February 2020, will be EuroAPI. It has also recruited Karl Rotthier from Centrient Pharmaceuticals, formerly DSM Sinochem, to be CEO. “

Addressing recent increasing medicine shortages that critically impact patient care, EuroAPI will ensure additional API supply capacities for Europe and beyond, and help balancing the industry’s heavy reliance on API sourced from other regions,” Sanofi stated.

Drug discovery firm Evotec, which also owns the CDMO Aptuit, has acquired the ‘Biopark by Sanofi’ (BBS) operation in Toulouse, France, and will rename it ‘Campus Curie’. The 19 employees are all transferring. Financial terms were not disclosed.

The company said that this acquisition will allow it “to significantly expand its existing capacities at the site over the near to mid-term while retaining maximum flexibility to build up long-term capacity as needed”.